Navigating Recent Advances in the Treatment and Management of Pancreatic Cancer: Expert Strategies for Patient-Centric Care

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2020 to January 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

Description:
Pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of all cancer deaths. In 2019, it is estimated that pancreatic cancer will be responsible for 45,750 deaths among 56,770 new cases. Despite treatment advances, pancreatic cancer is associated with a relatively poor outcome for most patients and remains one of the most challenging malignancies to treat. Fortunately for patients with pancreatic cancer, several new treatment options, including PARP inhibitors, have become available in recent years or have recently undergone successful late stage clinical trials. They have shown the ability to improve safety and efficacy outcomes, and significantly delay the progression of metastatic pancreatic cancer in patients with BRCA gene mutations. With the advancement and complexity of different treatment options, clinicians are increasingly able to select more potent—and soon, more targeted—options for managing this disease.

Upon completion of this activity, participants will be able to:

  • Analyze recent clinical trial data on the efficacy and safety of new and emerging therapies, including PARP inhibitors, for patients with pancreatic cancer

  • Assess the role of emerging PARP inhibitors in the evolving pancreatic cancer treatment paradigm

  • Identify patients with pancreatic cancer who are candidates for experimental targeted therapy options

  • Examine the evolving impact of BRCA1/2 testing on patients with pancreatic cancer for patient-centric care

  • Explore the managed care considerations of emerging targeted therapy options by exploring where these potential agents may fit into the current pancreatic management paradigm

  • Review adverse events associated with emerging therapies in pancreatic cancer, and select appropriate strategies to help ensure patient treatment adherence and optimal quality of life
     

Faculty: Andrew E. Hendifar, MD, MPH
Co-Director Pancreas Oncology
Gastrointestinal and Neuroendocrine Malignancies
Cedars-Sinai Medical Center

Disclosure:

Dr. Hendifar serves as a consultant for AbbVie, Ipsen, and Perthera. He has received grant/research support from Halozyme and Ipsen. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue